Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro DiagnosticsPOC Diagnostics

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1648506

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1648506

Point of Care Diagnostics Market by Product (Glucose, Infectious Disease, Pregnancy), Purchase Mode, Technology (Biochemistry, MDx ), Sample, End User - Global Forecast to 2029

PUBLISHED:
PAGES: 578 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

List of Tables

The point of care diagnostics market is estimated to reach USD 22.63 billion in 2029 from the forecasted value of USD 15.05 billion in 2024 at a CAGR of 8.5%. One of the primary reasons that will fuel POC testing is the favourable government initiatives and funding. Globally, governments consider these technologies essential in improving the accessibility of health care, bringing down costs, and enhancing outcomes for patients. Many governments also provide financial support in addition to the provision of grants with regulatory incentives to focus on the development and adoption of POC testing solutions. In developing countries with a lack of proper health care facilities, the governments encourage using POC devices abundantly, decentralizing tests for more underserved populations. Such supportive measures accelerate the adoption of POC diagnostics and thus are opening new market opportunities for diagnostic companies.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD)
SegmentsProduct, Mode of Purchase, Technology, Sample, and End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC Countries

"Infectious disease testing products segment is expected to have the fastest growth rate in the point of care diagnostics market, by product, during the forecast period."

The point of care diagnostics market is segmented into glucose monitoring products, cardiometabolic monitoring products, infectious disease testing products, coagulation monitoring products, pregnancy & fertility testing products, tumor/cancer marker testing products, urinalysis testing products, cholesterol testing products, hematology testing products, drugs-of-abuse testing products, thyroid stimulating hormone testing products, fecal occult testing products, and other products, based on product. Infectious disease testing products are expected to witness the fastest growth in the point of care diagnostics market, mainly driven by the high prevalence of infectious diseases worldwide. The increased demand for fast, accurate, and decentralized healthcare diagnostic solutions for community clinics and rural health centers has been driving the demand in this segment. Improved technologies that include faster molecular diagnostics and enhanced immunoassay platforms enhance the speed and efficiency of accuracy in POC testing. Moreover, with an increase in public health initiatives and growing awareness of the POC solutions for infectious diseases, adoption of these products is increasing significantly.

"Blood samples segment accounted for the largest market share in the point of care diagnostics market, by sample, during the forecast period."

Based on sample, the point of care diagnostics market is bifurcated into blood samples, urine samples, nasal and oropharyngeal swabs, and other samples. The largest market share is held by blood samples in the point of care diagnostics market. Their critical role lies in detecting the broad spectrum of conditions such as diabetes, cardiovascular diseases, infectious diseases, and metabolic disorders. Blood-based tests are considered accurate, reliable, and offer have high turnaround times for results. Because of this reason, these are the most opted sample type for both clinical and near-patient environments. Also, efficiency in blood-based POC devices has been enhanced by the technological advancements which result in accurate results with minimum sample volumes. Additionally, chronic and infectious diseases continue to be on rise, which is accompanied by a high demand for rapid and convenient diagnostic solutions requiring blood-based tests, which has helped maintain the dominance of blood samples in this market.

"Asia Pacific: The fastest-growing market for point of care diagnostics"

The worldwide market for point of care diagnostics is categorized into North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC countries. The Asia Pacific region is experiencing significant growth in the point of care diagnostics market due to several factors. Government efforts to promote early disease detection, prevention, and regular health check-ups is a key driver, with a number of initiatives that encourage widespread health screening and timely intervention. These efforts, coupled with the rising healthcare expenditure across the region, have increased the accessibility and demand for diagnostic solutions. The increasing numbers of chronic conditions, such as diabetes in countries such as India and China have also increased the demand for fast and accurate diagnostic equipment. Improving public health results by early diagnosis and management is enabling more healthcare systems to become involved in adopting POC diagnostics in this region.

The break-up of the profile of primary participants in the point of care diagnostics market:

  • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
  • By Designation: C-level - 27%, D-level - 18%, and Others - 55%
  • By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Other- 4%

The key players in this market are Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Danaher (US), QuidelOrtho Corporation (US), BD (US), Thermo Fisher Scientific Inc. (US), bioMerieux (France), BIOSYNEX SA (France), EKF Diagnostics Holdings plc (UK), Trinity Biotech (Ireland), Werfen (US), Nova Biomedical (US), SEKISUI Diagnostics (US), Boditech Med Inc. (South Korea), Grifols, S.A. (Spain), LifeScan IP Holdings, LLC (US), PTS Diagnostics (US), Eurolyser Diagnostica GmbH (Austria), Response Biomedical (Canada), Alfa Scientific Designs, Inc. (US), BTNX Inc. (Canada), Ascensia Diabetes Care Holdings AG (Switzerland), Fluxergy (US), Precision Biosensor, Inc. (South Korea), ACON Laboratories, Inc. (US), Menarini Diagnostics s.r.l (Italy), OraSure Technologies, Inc. (US), and Mankind Pharma (India) .

Research Coverage:

This research report categorizes the point of care diagnostics market by product (glucose monitoring products, cardiometabolic monitoring products, infectious disease testing products, coagulation monitoring products, pregnancy & fertility testing products, tumor/cancer marker testing products, urinalysis testing products, cholesterol testing products, hematology testing products, drugs-of-abuse testing products, thyroid stimulating hormone testing products, fecal occult testing products, and other products), by mode of purchase (OTC testing products and prescription-based testing products), by technology (immunoassays, molecular diagnostics, and biochemistry), by sample (blood samples, urine samples, nasal & oropharyngeal swabs, and other samples), by end user (clinical laboratories, ambulatory care facilities and physician offices, hospitals, critical care centers, and urgent care centers; home care settings and self-testing, and other end users) and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the point of care diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the point of care diagnostics market. Competitive analysis of upcoming startups in the point of care diagnostics market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall point of care diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (Growing incidence of infectious disease, increasing prevalence of chronic diseases, favourable government initiatives for point of care testing, and rising number of waived tests), opportunities (Increasing growth potential in emerging markets, rising inclination toward decentralized healthcare system, booming healthcare spending worldwide), restraints (Pricing pressure on manufacturers and stringent regulatory approval process for product commercialization), and challenges (Inadequate standardization with centralized lab methods and premium pricing of novel platforms) influencing the growth of the point of care diagnostics market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the point of care diagnostics market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the point of care diagnostics market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the point of care diagnostics market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), QuidelOrtho Corporation (US), and Danaher (US).
Show more
Product Code: MD 2702

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION AND REGIONS COVERED
    • 1.3.2 INCLUSIONS AND EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH APPROACH
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key secondary sources
      • 2.2.1.2 Key data from secondary sources
      • 2.2.1.3 Objectives
    • 2.2.2 PRIMARY DATA
      • 2.2.2.1 Key primary sources
      • 2.2.2.2 Key data from primary sources
      • 2.2.2.3 Key industry insights
      • 2.2.2.4 Breakdown of primary interviews
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
      • 2.3.1.1 Company revenue estimation approach
      • 2.3.1.2 Presentations of companies and primary interviews
      • 2.3.1.3 Growth forecast
      • 2.3.1.4 CAGR projections
    • 2.3.2 TOP-DOWN APPROACH
  • 2.4 DATA TRIANGULATION
  • 2.5 MARKET SHARE ANALYSIS
  • 2.6 RESEARCH ASSUMPTIONS
    • 2.6.1 PARAMETRIC ASSUMPTIONS
    • 2.6.2 GROWTH RATE ASSUMPTIONS
  • 2.7 RESEARCH LIMITATIONS
  • 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 POINT OF CARE DIAGNOSTICS MARKET OVERVIEW
  • 4.2 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2024 VS. 2029
  • 4.3 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024 VS. 2029
  • 4.4 POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029
  • 4.5 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2024 VS. 2029
  • 4.6 POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029
  • 4.7 POINT OF CARE DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing incidence of infectious diseases
      • 5.2.1.2 Increasing prevalence of chronic diseases
      • 5.2.1.3 Favorable government initiatives for point of care testing
      • 5.2.1.4 Rising number of waived tests
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Pricing pressure on manufacturers
      • 5.2.2.2 Stringent regulatory approval process for product commercialization
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increasing growth potential in emerging markets
      • 5.2.3.2 Rising inclination toward decentralized healthcare system
      • 5.2.3.3 Booming healthcare spending worldwide
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Inadequate standardization with centralized lab methods
      • 5.2.4.2 Premium pricing of novel platforms
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.4 PRICING ANALYSIS
    • 5.4.1 AVERAGE SELLING PRICE, BY PRODUCT
    • 5.4.2 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER
    • 5.4.3 AVERAGE SELLING PRICE, BY REGION
      • 5.4.3.1 Average selling price of glucose monitoring test strips, by region
      • 5.4.3.2 Average selling price of infectious disease testing products, by region
      • 5.4.3.3 Average selling price of cardiometabolic monitoring products, by region
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 INVESTMENT AND FUNDING SCENARIO
  • 5.9 TECHNOLOGY ANALYSIS
    • 5.9.1 KEY TECHNOLOGIES
      • 5.9.1.1 Immunoassays
    • 5.9.2 COMPLEMENTARY TECHNOLOGIES
      • 5.9.2.1 Molecular diagnostics
    • 5.9.3 ADJACENT TECHNOLOGIES
      • 5.9.3.1 Biochemical technologies
  • 5.10 PATENT ANALYSIS
  • 5.11 TRADE ANALYSIS
    • 5.11.1 IMPORT DATA FOR HS CODE 3822
    • 5.11.2 EXPORT DATA FOR HS CODE 3822
  • 5.12 KEY CONFERENCES AND EVENTS, 2025-2026
  • 5.13 PORTER'S FIVE FORCES ANALYSIS
    • 5.13.1 BARGAINING POWER OF SUPPLIERS
    • 5.13.2 BARGAINING POWER OF BUYERS
    • 5.13.3 THREAT OF NEW ENTRANTS
    • 5.13.4 THREAT OF SUBSTITUTES
    • 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.14.2 KEY BUYING CRITERIA
  • 5.15 IMPACT OF AI ON POINT OF CARE DIAGNOSTICS MARKET
    • 5.15.1 INTRODUCTION
    • 5.15.2 MARKET POTENTIAL OF AI IN POINT OF CARE DIAGNOSTICS MARKET
    • 5.15.3 AI USE CASES
    • 5.15.4 KEY COMPANIES IMPLEMENTING AI
    • 5.15.5 FUTURE OF AI IN POINT OF CARE DIAGNOSTICS MARKET
  • 5.16 REGULATORY LANDSCAPE
    • 5.16.1 REGULATORY ANALYSIS
      • 5.16.1.1 North America
        • 5.16.1.1.1 US
        • 5.16.1.1.2 Canada
      • 5.16.1.2 Europe
        • 5.16.1.2.1 Germany
        • 5.16.1.2.2 UK
        • 5.16.1.2.3 France
        • 5.16.1.2.4 Italy
        • 5.16.1.2.5 Spain
      • 5.16.1.3 Asia Pacific
        • 5.16.1.3.1 China
        • 5.16.1.3.2 Japan
        • 5.16.1.3.3 India
        • 5.16.1.3.4 Australia
        • 5.16.1.3.5 South Korea
      • 5.16.1.4 Latin America
        • 5.16.1.4.1 Brazil
        • 5.16.1.4.2 Mexico
      • 5.16.1.5 Middle East
        • 5.16.1.5.1 Africa
    • 5.16.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.17 CASE STUDY ANALYSIS
    • 5.17.1 CASE STUDY 1: IMPACT OF POINT OF CARE PCR TESTING FOR COMMUNITY-ACQUIRED PNEUMONIA IN DENMARK
    • 5.17.2 CASE STUDY 2: ASSESSING POINT OF CARE VIRAL LOAD TESTING IMPACT ON HIV MONITORING IN NIGERIA
    • 5.17.3 CASE STUDY 3: CLINICAL IMPACT OF ROUTINE MOLECULAR POINT OF CARE TEST FOR INFLUENZA IN HOSPITALIZED ADULTS

6 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 GLUCOSE MONITORING PRODUCTS
    • 6.2.1 GLUCOSE MONITORING STRIPS
      • 6.2.1.1 Growing trend toward preventive healthcare to drive market
    • 6.2.2 GLUCOSE MONITORING METERS
      • 6.2.2.1 Growing technological advancements in glucose meters to propel market
    • 6.2.3 GLUCOSE MONITORING LANCETS & LANCING DEVICES
      • 6.2.3.1 Increasing tendency for home-based care and self-monitoring to aid growth
  • 6.3 CARDIOMETABOLIC MONITORING PRODUCTS
    • 6.3.1 CARDIAC MARKER TESTING PRODUCTS
      • 6.3.1.1 Growing government support for cardiovascular diseases to drive market
    • 6.3.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS
      • 6.3.2.1 Need to optimize hospital workflow to favor growth
    • 6.3.3 HBA1C TESTING PRODUCTS
      • 6.3.3.1 Increasing recommendations by government healthcare authorities to boost market
  • 6.4 INFECTIOUS DISEASE TESTING PRODUCTS
    • 6.4.1 RESPIRATORY INFECTION TESTING PRODUCTS
      • 6.4.1.1 Influenza testing products
        • 6.4.1.1.1 Need for targeted treatments to expedite growth
      • 6.4.1.2 Tuberculosis
        • 6.4.1.2.1 Increasing demand for diagnostic products and services to contribute to growth
      • 6.4.1.3 Other respiratory infection testing products
    • 6.4.2 HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS
      • 6.4.2.1 Growing rate of surgical-site infections to boost market
    • 6.4.3 TROPICAL DISEASE TESTING PRODUCTS
      • 6.4.3.1 Rising incidence of malaria and dengue to support growth
    • 6.4.4 SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS
      • 6.4.4.1 HIV testing products
        • 6.4.4.1.1 Growing availability and awareness of testing products to boost market
      • 6.4.4.2 Hepatitis testing products
        • 6.4.4.2.1 Hepatitis B testing products
          • 6.4.4.2.1.1 Increasing prevalence of liver infections to favor growth
        • 6.4.4.2.2 Hepatitis C testing products
          • 6.4.4.2.2.1 Need to combat hepatitis among high-risk subgroup populations to aid growth
      • 6.4.4.3 Syphilis testing products
        • 6.4.4.3.1 Need for early and accessible diagnosis to expedite growth
      • 6.4.4.4 Human papillomavirus testing products
        • 6.4.4.4.1 Rising cases of cervical cancer to promote growth
      • 6.4.4.5 Chlamydia trachomatis testing products
        • 6.4.4.5.1 Growing adoption of advanced techniques to drive market
      • 6.4.4.6 Neisseria gonorrhea testing products
        • 6.4.4.6.1 Rising incidence of gonorrhea and antimicrobial resistance to augment growth
      • 6.4.4.7 Herpes simplex virus testing products
        • 6.4.4.7.1 Increasing incidence of herpes to support growth
    • 6.4.5 CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS
      • 6.4.5.1 Rising cases among hospitalized patients to boost demand
    • 6.4.6 OTHER INFECTIOUS DISEASE TESTING PRODUCTS
  • 6.5 COAGULATION MONITORING PRODUCTS
    • 6.5.1 PT/INR TESTING PRODUCTS
      • 6.5.1.1 Increasing number of atrial fibrillation cases to accelerate growth
    • 6.5.2 ACT/APTT TESTING PRODUCTS
      • 6.5.2.1 Rise in surgical procedures to speed up growth
  • 6.6 PREGNANCY & FERTILITY TESTING PRODUCTS
    • 6.6.1 PREGNANCY TESTING PRODUCTS
      • 6.6.1.1 Increasing awareness about family planning to stimulate growth
    • 6.6.2 FERTILITY TESTING PRODUCTS
      • 6.6.2.1 Growing infertility issues to fuel market
  • 6.7 TUMOR/CANCER MARKER TESTING PRODUCTS
    • 6.7.1 GROWING INVESTMENTS IN CANCER RESEARCH TO DRIVE MARKET
  • 6.8 URINALYSIS TESTING PRODUCTS
    • 6.8.1 INCREASING PREVALENCE OF URINARY TRACT INFECTIONS TO AUGMENT GROWTH
  • 6.9 CHOLESTEROL TESTING PRODUCTS
    • 6.9.1 RISING OBESITY AND CARDIOVASCULAR DISEASES TO FOSTER GROWTH
  • 6.10 HEMATOLOGY TESTING PRODUCTS
    • 6.10.1 INCREASING CASES OF ANEMIA TO SUSTAIN GROWTH
  • 6.11 DRUGS-OF-ABUSE TESTING PRODUCTS
    • 6.11.1 GROWING CONSUMPTION OF ILLICIT DRUGS TO FAVOR MARKET
  • 6.12 THYROID-STIMULATING HORMONE TESTING PRODUCTS
    • 6.12.1 RISING PREVALENCE OF THYROID TO ENCOURAGE GROWTH
  • 6.13 FECAL OCCULT TESTING PRODUCTS
    • 6.13.1 GROWING INCIDENCE OF CANCER TO PROPEL MARKET
  • 6.14 OTHER PRODUCTS

7 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE

  • 7.1 INTRODUCTION
  • 7.2 PRESCRIPTION-BASED TESTING PRODUCTS
    • 7.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO AUGMENT GROWTH
  • 7.3 OTC TESTING PRODUCTS
    • 7.3.1 GROWING PATIENT PREFERENCE FOR REMOTE HEALTHCARE TO PROPEL MARKET

8 POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 8.1 INTRODUCTION
  • 8.2 BIOCHEMISTRY
    • 8.2.1 INCREASING PREVALENCE OF URINARY TRACT INFECTIONS TO EXPEDITE GROWTH
  • 8.3 IMMUNOASSAYS
    • 8.3.1 GROWING INCLINATION TOWARD DECENTRALIZED HEALTHCARE TO DRIVE MARKET
  • 8.4 MOLECULAR DIAGNOSTICS
    • 8.4.1 RT-PCR
      • 8.4.1.1 Growing use of RT-PCR in proteomics and genomics to boost market
    • 8.4.2 INAAT
      • 8.4.2.1 Emerging new pathogens to facilitate growth

9 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE

  • 9.1 INTRODUCTION
  • 9.2 BLOOD SAMPLES
    • 9.2.1 GROWING APPLICATION OF BLOOD SAMPLES IN DISEASE DETECTION TO DRIVE MARKET
  • 9.3 NASAL & OROPHARYNGEAL SWABS
    • 9.3.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO AID GROWTH
  • 9.4 URINE SAMPLES
    • 9.4.1 NEED FOR EARLY DETECTION AND MONITORING OF DIABETES-RELATED COMPLICATIONS TO PROPEL MARKET
  • 9.5 OTHER SAMPLES

10 POINT OF CARE DIAGNOSTICS MARKET, BY END USER

  • 10.1 INTRODUCTION
  • 10.2 HOME CARE SETTINGS AND SELF-TESTING
    • 10.2.1 INCREASING PREFERENCE AMONG WOMEN FOR CONFIDENTIALITY AND ACCESSIBILITY TO SUPPORT GROWTH
  • 10.3 CLINICAL LABORATORIES
    • 10.3.1 GROWING IMPROVEMENTS IN AUTOMATED TESTING SERVICES TO BOOST MARKET
  • 10.4 HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS
    • 10.4.1 RISING DEMAND FOR FAST DIAGNOSTIC SOLUTIONS TO SPUR GROWTH
  • 10.5 AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES
    • 10.5.1 NEED FOR RAPID RESULT GENERATION AND IMMEDIATE PATIENT CARE TO AID GROWTH
  • 10.6 OTHER END USERS

11 POINT OF CARE DIAGNOSTICS MARKET, BY REGION

  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 11.2.2 US
      • 11.2.2.1 Presence of advanced healthcare infrastructure and high healthcare expenditures to aid growth
    • 11.2.3 CANADA
      • 11.2.3.1 Rising incidence of diabetes and infectious diseases to support growth
  • 11.3 EUROPE
    • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 11.3.2 GERMANY
      • 11.3.2.1 Increasing need for rapid and accurate diagnostic solutions to promote growth
    • 11.3.3 FRANCE
      • 11.3.3.1 Growing demand for accessible and convenient diagnostic tools to propel market
    • 11.3.4 UK
      • 11.3.4.1 Rising number of accredited clinical and hospital laboratories to sustain growth
    • 11.3.5 ITALY
      • 11.3.5.1 Growing burden of infectious and parasitic diseases to boost market
    • 11.3.6 SPAIN
      • 11.3.6.1 Rising prevalence of circulatory system diseases to contribute to growth
    • 11.3.7 REST OF EUROPE
  • 11.4 ASIA PACIFIC
    • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 11.4.2 CHINA
      • 11.4.2.1 Increasing impact of diabetes on public health to amplify growth
    • 11.4.3 JAPAN
      • 11.4.3.1 Booming geriatric population to stimulate growth
    • 11.4.4 INDIA
      • 11.4.4.1 Increasing cases of chronic heart and kidney diseases to foster growth
    • 11.4.5 AUSTRALIA
      • 11.4.5.1 Growing research investments for next-gen point of care devices to boost market
    • 11.4.6 SOUTH KOREA
      • 11.4.6.1 Growing focus on innovative diagnostic products to drive market
    • 11.4.7 REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 11.5.2 BRAZIL
      • 11.5.2.1 Increasing public initiatives in healthcare to encourage growth
    • 11.5.3 MEXICO
      • 11.5.3.1 Need for frequent testing for disease management to expedite growth
    • 11.5.4 REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    • 11.6.1 GROWING OUTBREAKS OF INFECTIOUS DISEASES AND EMPHASIS ON PREVENTIVE HEALTHCARE TO DRIVE MARKET
    • 11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.7 GCC COUNTRIES
    • 11.7.1 BOOMING HEALTHCARE INFRASTRUCTURE TO FACILITATE GROWTH
    • 11.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

12 COMPETITIVE LANDSCAPE

  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN POINT OF CARE DIAGNOSTICS MARKET
  • 12.3 REVENUE ANALYSIS, 2021-2023
  • 12.4 MARKET SHARE ANALYSIS, 2023
  • 12.5 COMPANY VALUATION AND FINANCIAL METRICS
  • 12.6 BRAND/PRODUCT COMPARISON
    • 12.6.1 ABBOTT
    • 12.6.2 F. HOFFMANN-LA ROCHE LTD.
    • 12.6.3 NOVA BIOMEDICAL
  • 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 12.7.1 STARS
    • 12.7.2 EMERGING LEADERS
    • 12.7.3 PERVASIVE PLAYERS
    • 12.7.4 PARTICIPANTS
    • 12.7.5 COMPANY FOOTPRINT, KEY PLAYERS, 2023
      • 12.7.5.1 Company footprint
      • 12.7.5.2 Region footprint
      • 12.7.5.3 Mode of purchase footprint
      • 12.7.5.4 Technology footprint
      • 12.7.5.5 Sample footprint
  • 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 12.8.1 PROGRESSIVE COMPANIES
    • 12.8.2 RESPONSIVE COMPANIES
    • 12.8.3 DYNAMIC COMPANIES
    • 12.8.4 STARTING BLOCKS
  • 12.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 12.9.1 DETAILED LIST OF KEY STARTUPS/SMES
    • 12.9.2 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
  • 12.10 COMPETITIVE SCENARIO
    • 12.10.1 PRODUCT LAUNCHES AND APPROVALS
    • 12.10.2 DEALS

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
    • 13.1.1 ABBOTT
      • 13.1.1.1 Business overview
      • 13.1.1.2 Products offered
      • 13.1.1.3 Recent developments
        • 13.1.1.3.1 Product launches and approvals
        • 13.1.1.3.2 Deals
      • 13.1.1.4 MnM view
        • 13.1.1.4.1 Right to win
        • 13.1.1.4.2 Strategic choices
        • 13.1.1.4.3 Weaknesses and competitive threats
    • 13.1.2 SIEMENS HEALTHINEERS AG
      • 13.1.2.1 Business overview
      • 13.1.2.2 Products offered
      • 13.1.2.3 Recent developments
        • 13.1.2.3.1 Product launches and approvals
        • 13.1.2.3.2 Deals
        • 13.1.2.3.3 Expansions
      • 13.1.2.4 MnM view
        • 13.1.2.4.1 Right to win
        • 13.1.2.4.2 Strategic choices
        • 13.1.2.4.3 Weaknesses and competitive threats
    • 13.1.3 F. HOFFMANN-LA ROCHE LTD
      • 13.1.3.1 Business overview
      • 13.1.3.2 Products offered
      • 13.1.3.3 Recent developments
        • 13.1.3.3.1 Product launches and approvals
        • 13.1.3.3.2 Deals
        • 13.1.3.3.3 Expansions
      • 13.1.3.4 MnM view
        • 13.1.3.4.1 Right to win
        • 13.1.3.4.2 Strategic choices
        • 13.1.3.4.3 Weaknesses and competitive threats
    • 13.1.4 DANAHER
      • 13.1.4.1 Business overview
      • 13.1.4.2 Products offered
      • 13.1.4.3 Recent developments
        • 13.1.4.3.1 Deals
      • 13.1.4.4 MnM view
        • 13.1.4.4.1 Key strengths
        • 13.1.4.4.2 Strategic choices
        • 13.1.4.4.3 Weaknesses and competitive threats
    • 13.1.5 QUIDELORTHO CORPORATION
      • 13.1.5.1 Business overview
      • 13.1.5.2 Products offered
      • 13.1.5.3 Recent developments
        • 13.1.5.3.1 Product launches and approvals
        • 13.1.5.3.2 Deals
        • 13.1.5.3.3 Expansions
      • 13.1.5.4 MnM view
        • 13.1.5.4.1 Right to win
        • 13.1.5.4.2 Strategic choices
        • 13.1.5.4.3 Weaknesses and competitive threats
    • 13.1.6 BD
      • 13.1.6.1 Business overview
      • 13.1.6.2 Products offered
      • 13.1.6.3 Recent developments
        • 13.1.6.3.1 Deals
        • 13.1.6.3.2 Expansions
    • 13.1.7 THERMO FISHER SCIENTIFIC INC.
      • 13.1.7.1 Business overview
      • 13.1.7.2 Products offered
      • 13.1.7.3 Recent developments
        • 13.1.7.3.1 Product launches and approvals
        • 13.1.7.3.2 Deals
    • 13.1.8 BIOMERIEUX
      • 13.1.8.1 Business overview
      • 13.1.8.2 Products offered
      • 13.1.8.3 Recent developments
        • 13.1.8.3.1 Product launches and approvals
        • 13.1.8.3.2 Deals
    • 13.1.9 BIOSYNEX SA
      • 13.1.9.1 Business overview
      • 13.1.9.2 Products offered
      • 13.1.9.3 Recent developments
        • 13.1.9.3.1 Deals
    • 13.1.10 EKF DIAGNOSTICS HOLDINGS PLC
      • 13.1.10.1 Business overview
      • 13.1.10.2 Products offered
      • 13.1.10.3 Recent developments
        • 13.1.10.3.1 Product launches and approvals
        • 13.1.10.3.2 Deals
        • 13.1.10.3.3 Expansions
    • 13.1.11 TRINITY BIOTECH
      • 13.1.11.1 Business overview
      • 13.1.11.2 Products offered
      • 13.1.11.3 Recent developments
        • 13.1.11.3.1 Product launches and approvals
        • 13.1.11.3.2 Deals
    • 13.1.12 WERFEN
      • 13.1.12.1 Business overview
      • 13.1.12.2 Products offered
      • 13.1.12.3 Recent developments
        • 13.1.12.3.1 Product launches and approvals
        • 13.1.12.3.2 Deals
    • 13.1.13 NOVA BIOMEDICAL
      • 13.1.13.1 Business overview
      • 13.1.13.2 Products offered
      • 13.1.13.3 Recent developments
        • 13.1.13.3.1 Product launches and approvals
        • 13.1.13.3.2 Expansions
    • 13.1.14 SEKISUI DIAGNOSTICS
      • 13.1.14.1 Business overview
      • 13.1.14.2 Products offered
    • 13.1.15 BODITECH MED INC.
      • 13.1.15.1 Business overview
      • 13.1.15.2 Products offered
      • 13.1.15.3 Recent developments
        • 13.1.15.3.1 Product launches and approvals
        • 13.1.15.3.2 Deals
        • 13.1.15.3.3 Expansions
  • 13.2 OTHER PLAYERS
    • 13.2.1 GRIFOLS, S.A.
    • 13.2.2 LIFESCAN IP HOLDINGS, LLC
    • 13.2.3 PTS DIAGNOSTICS
    • 13.2.4 EUROLYSER DIAGNOSTICA GMBH
    • 13.2.5 RESPONSE BIOMEDICAL
    • 13.2.6 ALFA SCIENTIFIC DESIGNS, INC.
    • 13.2.7 BTNX INC.
    • 13.2.8 ASCENSIA DIABETES CARE HOLDINGS AG
    • 13.2.9 FLUXERGY
    • 13.2.10 PRECISION BIOSENSOR, INC.
    • 13.2.11 ACON LABORATORIES, INC.
    • 13.2.12 MENARINI DIAGNOSTICS S.R.L
    • 13.2.13 ORASURE TECHNOLOGIES, INC.
    • 13.2.14 MANKIND PHARMA

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
Show more
Product Code: MD 2702

List of Tables

  • TABLE 1 POINT OF CARE DIAGNOSTICS MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 POINT OF CARE DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES
  • TABLE 3 POINT OF CARE DIAGNOSTICS MARKET: RISK ASSESSMENT
  • TABLE 4 PROJECTED INCREASE OF CANCER PATIENTS, BY REGION, 2022 VS. 2035 VS. 2045
  • TABLE 5 GLOBAL DIABETES ESTIMATES (AGES 20-79) BY REGION, 2021 VS. 2030 VS. 2045 (IN THOUSANDS)
  • TABLE 6 PRODUCT WAIVERS, BY KEY PLAYER, 2021-2024
  • TABLE 7 AVERAGE SELLING PRICE OF POINT OF CARE TESTS, BY PRODUCT, 2022-2024
  • TABLE 8 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER, 2022-2024
  • TABLE 9 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY REGION, 2022-2024
  • TABLE 10 AVERAGE SELLING PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2022-2024
  • TABLE 11 AVERAGE SELLING PRICE OF CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2022-2024
  • TABLE 12 POINT OF CARE DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 13 POINT OF CARE DIAGNOSTICS MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2022-2023
  • TABLE 14 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019-2023 (USD MILLION)
  • TABLE 15 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019-2023 (USD MILLION)
  • TABLE 16 POINT OF CARE DIAGNOSTICS MARKET: KEY CONFERENCES AND EVENTS, 2025-2026
  • TABLE 17 POINT OF CARE DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY (%)
  • TABLE 19 KEY BUYING CRITERIA, BY TECHNOLOGY
  • TABLE 20 EUROPE: CLASSIFICATION OF IVD DEVICES
  • TABLE 21 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 22 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 23 AUSTRALIA: CLASSIFICATION OF IVD MEDICAL DEVICES
  • TABLE 24 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 25 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 26 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 28 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 29 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 30 DIABETES-RELATED HEALTH EXPENDITURE PER PERSON, 2021 VS. 2030 VS. 2045 (USD)
  • TABLE 31 POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 32 POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 33 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 34 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 35 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 36 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 37 KEY GLUCOSE MONITORING STRIPS AVAILABLE WORLDWIDE
  • TABLE 38 POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 39 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 40 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 41 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 42 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 43 KEY GLUCOSE MONITORING METERS AVAILABLE WORLDWIDE
  • TABLE 44 POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 45 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 46 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 47 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 48 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 49 KEY GLUCOSE MONITORING LANCETS & LANCING DEVICES AVAILABLE WORLDWIDE
  • TABLE 50 POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 51 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 52 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 53 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 54 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 55 KEY CARDIOMETABOLIC MONITORING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 56 POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 57 POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 58 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 59 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 60 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 61 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 62 POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 63 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 64 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 65 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 66 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 67 POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 68 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 69 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 70 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 71 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 72 POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 73 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 74 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 75 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 76 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 77 POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 78 POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 79 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 80 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 81 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 82 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 83 POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 84 POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 85 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 86 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 87 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 88 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 89 KEY INFLUENZA TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 90 POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 91 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 92 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 93 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 94 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 95 KEY TUBERCULOSIS TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 96 POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 97 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 98 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 99 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 100 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 101 OTHER KEY RESPIRATORY INFECTIONS TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 102 POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 103 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 104 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 105 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 106 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 107 KEY HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 108 POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 109 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 110 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 111 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 112 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 113 KEY TROPICAL DISEASE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 114 POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 115 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 116 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 118 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 119 POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 120 POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 121 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 122 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 124 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 125 KEY HIV TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 126 POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 127 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 128 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 129 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 130 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 131 POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 132 POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 133 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 134 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 135 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 136 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 137 KEY HEPATITIS B TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 138 POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 139 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 140 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 141 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 142 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 143 KEY HEPATITIS C TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 144 POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 145 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 146 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 147 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 148 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 149 KEY SYPHILIS TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 150 POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 151 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 152 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 153 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 154 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 155 KEY HPV TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 156 POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 157 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 158 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 159 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 160 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 161 KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 162 POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 163 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 164 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 165 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 166 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 167 POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 168 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 169 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 170 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 171 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 172 KEY HSV TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 173 POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 174 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 175 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 176 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 177 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 178 KEY CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 179 POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 180 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 181 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 182 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 183 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 184 OTHER KEY INFECTIOUS DISEASE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 185 POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 186 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 187 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 188 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 189 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 190 KEY COAGULATION MONITORING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 191 POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 192 POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 193 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 194 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 195 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 196 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 197 POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 198 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 199 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 200 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 201 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 202 POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 203 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 204 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 205 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 206 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 207 POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 208 POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 209 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 210 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 211 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 212 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 213 KEY PREGNANCY TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 214 POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 215 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 216 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 217 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 218 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 219 KEY FERTILITY TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 220 POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 221 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 222 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 223 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 224 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 225 TYPES OF CANCER CASES WORLDWIDE, 2022 VS. 2045
  • TABLE 226 KEY TUMOR/CANCER MARKER TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 227 POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 228 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 229 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 230 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 231 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 232 KEY URINALYSIS TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 233 POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 234 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 235 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 236 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 237 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 238 KEY CHOLESTEROL TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 239 POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 240 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 241 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 242 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 243 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 244 KEY HEMATOLOGY TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 245 POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 246 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 247 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 248 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 249 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 250 KEY DRUGS-OF-ABUSE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 251 POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 252 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 253 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 254 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 255 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 256 POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 257 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 258 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 259 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 260 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 261 KEY FECAL OCCULT BLOOD TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 262 POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 263 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 264 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 265 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 266 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 267 KEY OTHER POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 268 POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 269 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 270 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 271 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 272 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 273 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
  • TABLE 274 KEY PRESCRIPTION-BASED TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 275 POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 276 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 277 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 278 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 279 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 280 KEY OTC TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 281 POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 282 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 283 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 284 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 285 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 286 POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 287 KEY BIOCHEMISTRY-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 288 POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 289 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 290 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 291 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 292 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 293 KEY IMMUNOASSAY-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 294 POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 295 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 296 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 297 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 298 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 299 POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 300 POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 301 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 302 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 303 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 304 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 305 KEY RT-PCR-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 306 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 307 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 308 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 309 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 310 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 311 KEY INAAT-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 312 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 313 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 314 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 315 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 316 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 317 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION)
  • TABLE 318 KEY BLOOD SAMPLE-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 319 POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 320 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 321 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 322 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 323 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 324 KEY NASAL AND OROPHARYNGEAL SWAB-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 325 POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 326 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 327 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 328 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 329 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 330 KEY URINE SAMPLE-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 331 POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 332 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 333 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 334 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 335 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 336 KEY OTHER SAMPLE-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 337 POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 338 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 339 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 340 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 341 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 342 POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 343 POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 344 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 345 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 346 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 347 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 348 POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 349 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 350 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 351 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 352 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 353 POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 354 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 355 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 356 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 357 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 358 POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 359 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 360 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 361 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 362 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 363 POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 364 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 365 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 366 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 367 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 368 POINT OF CARE DIAGNOSTICS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 369 NORTH AMERICA: MACROECONOMIC INDICATORS FOR POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 370 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 371 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 372 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 373 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 374 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 375 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 376 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 377 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 378 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 379 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 380 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
  • TABLE 381 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 382 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 383 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION)
  • TABLE 384 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 385 NORTH AMERICA: NUMBER OF WOMEN USING HOME PREGNANCY KITS, BY COUNTRY, 2022-2029 (MILLION UNIT)
  • TABLE 386 US: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 387 US: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 388 US: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 389 US: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 390 US: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 391 US: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 392 US: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 393 US: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 394 US: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 395 US: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
  • TABLE 396 US: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 397 US: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 398 US: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION)
  • TABLE 399 US: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 400 CANADA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 401 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 402 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 403 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 404 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 405 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 406 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 407 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 408 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 409 CANADA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
  • TABLE 410 CANADA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 411 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 412 CANADA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION)
  • TABLE 413 CANADA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 414 MACROECONOMIC INDICATORS FOR POINT OF CARE DIAGNOSTICS MARKET IN EUROPE
  • TABLE 415 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 416 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 417 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 418 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 419 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 420 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 421 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 422 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 423 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 424 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 425 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
  • TABLE 426 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 427 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 428 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION)
  • TABLE 429 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 430 GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 431 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 432 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 433 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 434 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 435 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 436 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 437 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 438 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 439 GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
  • TABLE 440 GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 441 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 442 GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION)
  • TABLE 443 GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 444 FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 445 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 446 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 447 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 448 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 449 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 450 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 451 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 452 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 453 FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
  • TABLE 454 FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 455 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 456 FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION)
  • TABLE 457 FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 458 UK: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 459 UK: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 460 UK: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 461 UK: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 462 UK: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 463 UK: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 464 UK: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 465 UK: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 466 UK: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 467 UK: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
  • TABLE 468 UK: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 469 UK: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 470 UK: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION)
  • TABLE 471 UK: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 472 ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 473 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 474 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 475 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 476 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 477 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 478 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 479 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 480 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 481 ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
  • TABLE 482 ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 483 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 484 ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION)
  • TABLE 485 ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 486 SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 487 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 488 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 489 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 490 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 491 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 492 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 493 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 494 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 495 SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
  • TABLE 496 SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 497 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 498 SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION)
  • TABLE 499 SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 500 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 501 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 502 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 503 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 504 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 505 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 506 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 507 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 508 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 509 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
  • TABLE 510 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 511 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 512 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION)
  • TABLE 513 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 514 ASIA PACIFIC: MACROECONOMIC INDICATORS FOR POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 515 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 516 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 517 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 518 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 519 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 520 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 521 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 522 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 523 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 524 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 525 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
  • TABLE 526 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 527 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 528 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION)
  • TABLE 529 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 530 CHINA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 531 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 532 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 533 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 534 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 535 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 536 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 537 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 538 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 539 CHINA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
  • TABLE 540 CHINA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 541 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 542 CHINA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION)
  • TABLE 543 CHINA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 544 JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 545 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 546 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 547 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 548 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 549 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 550 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 551 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 552 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 553 JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
  • TABLE 554 JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 555 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 556 JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION)
  • TABLE 557 JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 558 INDIA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 559 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 560 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 561 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 562 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 563 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 564 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 565 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 566 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 567 INDIA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
  • TABLE 568 INDIA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 569 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 570 INDIA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION)
  • TABLE 571 INDIA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 572 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 573 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 574 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 575 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 576 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 577 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 578 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 579 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 580 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 581 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
  • TABLE 582 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 583 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 584 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION)
  • TABLE 585 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 586 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 587 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 588 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 589 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 590 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 591 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 592 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 593 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 594 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 595 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
  • TABLE 596 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 597 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 598 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION)
  • TABLE 599 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 600 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 601 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 602 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 603 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 604 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 605 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE,2022-2029 (USD MILLION)
  • TABLE 606 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 607 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 608 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 609 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
  • TABLE 610 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 611 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 612 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION)
  • TABLE 613 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 614 MACROECONOMIC INDICATORS FOR POINT OF CARE DIAGNOSTICS MARKET IN LATIN AMERICA
  • TABLE 615 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 616 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 617 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 618 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 619 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 620 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 621 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 622 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 623 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 624 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 625 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
  • TABLE 626 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 627 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 628 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION)
  • TABLE 629 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 630 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 631 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 632 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 633 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 634 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 635 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 636 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 637 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 638 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 639 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
  • TABLE 640 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 641 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 642 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION)
  • TABLE 643 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 644 MEXICO: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 645 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 646 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 647 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 648 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 649 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 650 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 651 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 652 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 653 MEXICO: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
  • TABLE 654 MEXICO: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 655 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 656 MEXICO: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION)
  • TABLE 657 MEXICO: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 658 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 659 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 660 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 661 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 662 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 663 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 664 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 665 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 666 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 667 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
  • TABLE 668 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 669 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 670 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION)
  • TABLE 671 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 672 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 673 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 674 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 675 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 676 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 677 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 678 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 679 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 680 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 681 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
  • TABLE 682 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 683 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 684 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION)
  • TABLE 685 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 686 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
  • TABLE 687 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 688 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 689 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 690 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 691 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 692 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 693 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 694 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 695 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 696 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
  • TABLE 697 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 698 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 699 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION)
  • TABLE 700 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 701 GCC COUNTRIES: MACROECONOMIC INDICATORS
  • TABLE 702 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN POINT OF CARE DIAGNOSTICS MARKET, JANUARY 2021-NOVEMBER 2024
  • TABLE 703 POINT OF CARE DIAGNOSTICS MARKET: DEGREE OF COMPETITION
  • TABLE 704 POINT OF CARE DIAGNOSTICS MARKET: REGION FOOTPRINT
  • TABLE 705 POINT OF CARE DIAGNOSTICS MARKET: MODE OF PURCHASE FOOTPRINT
  • TABLE 706 POINT OF CARE DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 707 POINT OF CARE DIAGNOSTICS MARKET: SAMPLE FOOTPRINT
  • TABLE 708 POINT OF CARE DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 709 POINT OF CARE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)
  • TABLE 710 POINT OF CARE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)
  • TABLE 711 POINT OF CARE DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 712 POINT OF CARE DIAGNOSTICS MARKET: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 713 ABBOTT: COMPANY OVERVIEW
  • TABLE 714 ABBOTT: PRODUCTS OFFERED
  • TABLE 715 ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 716 ABBOTT: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 717 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 718 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
  • TABLE 719 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 720 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 721 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
  • TABLE 722 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
  • TABLE 723 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
  • TABLE 724 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 725 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 726 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
  • TABLE 727 DANAHER: COMPANY OVERVIEW
  • TABLE 728 DANAHER: PRODUCTS OFFERED
  • TABLE 729 DANAHER: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 730 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
  • TABLE 731 QUIDELORTHO CORPORATION: PRODUCTS OFFERED
  • TABLE 732 QUIDELORTHO CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 733 QUIDELORTHO CORPORATION: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 734 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
  • TABLE 735 BD: COMPANY OVERVIEW
  • TABLE 736 BD: PRODUCTS OFFERED
  • TABLE 737 BD: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 738 BD: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
  • TABLE 739 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 740 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 741 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 742 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 743 BIOMERIEUX: COMPANY OVERVIEW
  • TABLE 744 BIOMERIEUX: PRODUCTS OFFERED
  • TABLE 745 BIOMERIEUX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 746 BIOMERIEUX: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 747 BIOSYNEX SA: COMPANY OVERVIEW
  • TABLE 748 BIOSYNEX SA: PRODUCTS OFFERED
  • TABLE 749 BIOSYNEX SA: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 750 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW
  • TABLE 751 EKF DIAGNOSTICS HOLDINGS PLC: PRODUCTS OFFERED
  • TABLE 752 EKF DIAGNOSTICS HOLDINGS PLC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 753 EKF DIAGNOSTICS HOLDINGS PLC: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 754 EKF DIAGNOSTICS HOLDINGS PLC: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
  • TABLE 755 TRINITY BIOTECH: COMPANY OVERVIEW
  • TABLE 756 TRINITY BIOTECH: PRODUCTS OFFERED
  • TABLE 757 TRINITY BIOTECH: PRODUCT APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 758 TRINITY BIOTECH: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 759 WERFEN: COMPANY OVERVIEW
  • TABLE 760 WERFEN: PRODUCTS OFFERED
  • TABLE 761 WERFEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 762 WERFEN: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 763 NOVA BIOMEDICAL: COMPANY OVERVIEW
  • TABLE 764 NOVA BIOMEDICAL: PRODUCTS OFFERED
  • TABLE 765 NOVA BIOMEDICAL: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 766 NOVA BIOMEDICAL: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
  • TABLE 767 SEKISUI DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 768 SEKISUI DIAGNOSTICS: PRODUCTS OFFERED
  • TABLE 769 BODITECH MED INC.: COMPANY OVERVIEW
  • TABLE 770 BODITECH MED INC.: PRODUCTS OFFERED
  • TABLE 771 BODITECH MED INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 772 BODITECH MED INC.: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 773 BODITECH MED INC.: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
  • TABLE 774 GRIFOLS, S.A.: COMPANY OVERVIEW
  • TABLE 775 LIFESCAN IP HOLDINGS, LLC: COMPANY OVERVIEW
  • TABLE 776 PTS DIAGNOSTICS : COMPANY OVERVIEW
  • TABLE 777 EUROLYSER DIAGNOSTICA GMBH: COMPANY OVERVIEW
  • TABLE 778 RESPONSE BIOMEDICAL: COMPANY OVERVIEW
  • TABLE 779 ALFA SCIENTIFIC DESIGNS, INC.: COMPANY OVERVIEW
  • TABLE 780 BTNX INC.: COMPANY OVERVIEW
  • TABLE 781 ASCENSIA DIABETES CARE HOLDINGS AG: COMPANY OVERVIEW
  • TABLE 782 FLUXERGY: COMPANY OVERVIEW
  • TABLE 783 PRECISION BIOSENSOR, INC.: COMPANY OVERVIEW
  • TABLE 784 ACON LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 785 MENARINI DIAGNOSTICS S.R.L: COMPANY OVERVIEW
  • TABLE 786 ORASURE TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 787 MANKIND PHARMA: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 POINT OF CARE DIAGNOSTICS MARKET SEGMENTATION AND REGIONS COVERED
  • FIGURE 2 POINT OF CARE DIAGNOSTICS MARKET: RESEARCH DESIGN
  • FIGURE 3 POINT OF CARE DIAGNOSTICS MARKET: KEY INDUSTRY INSIGHTS
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
  • FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 8 POINT OF CARE DIAGNOSTICS MARKET: TOP-DOWN APPROACH
  • FIGURE 9 POINT OF CARE DIAGNOSTICS MARKET: DATA TRIANGULATION METHODOLOGY
  • FIGURE 10 POINT OF CARE DIAGNOSTICS MARKET: PARAMETRIC ASSUMPTIONS
  • FIGURE 11 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
  • FIGURE 12 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 16 POINT OF CARE DIAGNOSTICS MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 17 RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET
  • FIGURE 18 GLUCOSE MONITORING PRODUCTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 19 PRESCRIPTION-BASED TESTING PRODUCTS TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 20 BIOCHEMISTRY SEGMENT TO WITNESS LARGEST MARKET SHARE DURING FORECAST PERIOD
  • FIGURE 21 BLOOD SAMPLES SEGMENT TO COMMAND LARGEST MARKET SHARE DURING FORECAST PERIOD
  • FIGURE 22 HOME CARE SETTINGS AND SELF-TESTING SEGMENT TO HOLD LARGEST MARKET SHARE IN 2029
  • FIGURE 23 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 24 POINT OF CARE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 25 REGIONAL INCIDENCE OF HIV, 2023
  • FIGURE 26 NEW REVENUE POCKETS FOR PLAYERS IN POINT OF CARE DIAGNOSTICS MARKET
  • FIGURE 27 POINT OF CARE DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 28 POINT OF CARE DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 29 POINT OF CARE DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 30 INVESTMENT AND FUNDING SCENARIO, 2021-2024
  • FIGURE 31 POINT OF CARE DIAGNOSTICS MARKET: PATENT ANALYSIS, JANUARY 2014-DECEMBER 2023
  • FIGURE 32 POINT OF CARE DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY
  • FIGURE 34 KEY BUYING CRITERIA, BY TECHNOLOGY
  • FIGURE 35 MARKET POTENTIAL OF AI IN POINT OF CARE DIAGNOSTICS MARKET
  • FIGURE 36 US: REGULATORY PROCESS FOR IVD DEVICES
  • FIGURE 37 CANADA: REGULATORY PROCESS FOR IVD DEVICES
  • FIGURE 38 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
  • FIGURE 39 INDIA: REGULATORY PROCESS FOR IVD DEVICES
  • FIGURE 40 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
  • FIGURE 41 PREVALENCE OF DIABETES IN IDF REGIONS AMONG 20-79 YEARS OF ADULTS, 2021 VS. 2045 (%)
  • FIGURE 42 PREVALENCE OF HEART AND CIRCULATORY DISEASE WORLDWIDE, 2021 (MILLION)
  • FIGURE 43 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 44 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 45 REVENUE ANALYSIS OF KEY PLAYERS IN POINT OF CARE DIAGNOSTICS MARKET 2021-2023
  • FIGURE 46 MARKET SHARE ANALYSIS OF KEY PLAYERS IN POINT OF CARE DIAGNOSTICS MARKET, 2023
  • FIGURE 47 EV/EBITDA OF KEY VENDORS, 2024
  • FIGURE 48 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024
  • FIGURE 49 POINT OF CARE DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 50 POINT OF CARE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 51 POINT OF CARE DIAGNOSTICS MARKET: COMPANY FOOTPRINT
  • FIGURE 52 POINT OF CARE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 53 ABBOTT: COMPANY SNAPSHOT (2023)
  • FIGURE 54 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023)
  • FIGURE 55 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2023)
  • FIGURE 56 DANAHER: COMPANY SNAPSHOT (2023)
  • FIGURE 57 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 58 BD: COMPANY SNAPSHOT (2023)
  • FIGURE 59 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 60 BIOMERIEUX: COMPANY SNAPSHOT (2023)
  • FIGURE 61 BIOSYNEX SA: COMPANY SNAPSHOT (2023)
  • FIGURE 62 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2023)
  • FIGURE 63 TRINITY BIOTECH: COMPANY SNAPSHOT (2023)
  • FIGURE 64 WERFEN: COMPANY SNAPSHOT (2023)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!